


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199187</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1522-1539</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of physiology. Heart and circulatory physiology</Title>
                <ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Aldosterone impairs coronary adenosine-mediated vasodilation via reduced functional expression of Ca<sup>2+</sup>-activated K<sup>+</sup> channels.</ArticleTitle>
            <ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00081.2019</ELocationID>
            <Abstract>
                <AbstractText>Elevated plasma aldosterone (Aldo) levels are associated with greater risk of cardiac ischemic events and cardiovascular mortality. Adenosine-mediated coronary vasodilation is a critical cardioprotective mechanism during ischemia, however, whether this response is impaired by increased Aldo is unclear. We hypothesize that chronic Aldo impairs coronary adenosine-mediated vasodilation via downregulation of vascular K<sup>+</sup> channels. Male C57BL/6J mice were treated with vehicle (Con) or subpressor Aldo for 4 weeks. Coronary artery function, assessed by wire myography, revealed Aldo-induced reductions in vasodilation to adenosine and the endothelium-dependent vasodilator acetylcholine, but not to the nitric oxide donor sodium nitroprusside. Coronary vasoconstriction to endothelin-1 and the thromboxane A<sub>2</sub> mimetic U-46619 were unchanged by Aldo. Additional mechanistic studies revealed impaired adenosine A<sub>2A</sub>, not A<sub>2B</sub>, receptor-dependent vasodilation by Aldo with a tendency for Aldo-induced reduction of coronary A<sub>2A</sub> gene expression. Adenylate cyclase inhibition attenuated coronary adenosine dilation but did not eliminate group differences and adenosine-stimulated vascular cAMP production was similar between Con and Aldo mice. Similarly, blockade of inward rectifier K<sup>+</sup> channels reduced but did not eliminate group differences in adenosine dilation whereas group differences were eliminated by blockade of Ca<sup>2+</sup>-activated K<sup>+</sup> (K<sub>Ca</sub>) channels that blunted and abrogated adenosine and A<sub>2A</sub>-dependent dilation, respectively. Gene expression of several coronary K<sub>Ca</sub> channels was reduced by Aldo. Together, these data demonstrate Aldo-induced impairment of adenosine-mediated coronary vasodilation involving blunted A<sub>2A</sub>-K<sub>Ca</sub>-dependent vasodilation, independent of blood pressure, providing important insights into the link between plasma Aldo and cardiac mortality and rationale for aldosterone antagonist use to preserve coronary microvascular function.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khan</LastName>
                    <ForeName>Maloree</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Missouri, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meuth</LastName>
                    <ForeName>Alex I</ForeName>
                    <Initials>AI</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Missouri, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Scott M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Missouri, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chandrasekar</LastName>
                    <ForeName>Bysani</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medicine, University of Missouri, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowles</LastName>
                    <ForeName>Douglas K</ForeName>
                    <Initials>DK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biomedical Sciences and Dalton Cardiovascular Research Center, University of Missouri, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bender</LastName>
                    <ForeName>Shawn B</ForeName>
                    <Initials>SB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomedical Sciences, University of Missouri, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
            <NlmUniqueID>100901228</NlmUniqueID>
            <ISSNLinking>0363-6135</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">acetylcholine</Keyword>
            <Keyword MajorTopicYN="N">barium</Keyword>
            <Keyword MajorTopicYN="N">cAMP</Keyword>
            <Keyword MajorTopicYN="N">inward rectifier K+ channel</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199187</ArticleId>
            <ArticleId IdType="doi">10.1152/ajpheart.00081.2019</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

